Re: Retention AgreementRetention Agreement • March 20th, 2017 • Cerulean Pharma Inc. • Pharmaceutical preparations • Massachusetts
As you know, Cerulean Pharma, Inc. (the “Company”) is exploring the possibility of a number of business opportunities and transactions. We recognize and appreciate the contributions you have made to the Company during your employment and want you to remain committed to and focused on the tasks that you are assigned during this time.
SUPPORT AGREEMENTSupport Agreement • March 20th, 2017 • Cerulean Pharma Inc. • Pharmaceutical preparations • Delaware
This SUPPORT AGREEMENT (this “Agreement”), dated as of March 19, 2017, is entered into by and among Daré Bioscience, Inc., a Delaware corporation (“Private Company”), and each Person set forth on Schedule A hereto (each, a “Stockholder”). All capitalized terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Purchase Agreement (as defined below).
Re: Retention AgreementClaims Agreement • March 20th, 2017 • Cerulean Pharma Inc. • Pharmaceutical preparations • Massachusetts
As you know, Cerulean Pharma, Inc. (the “Company”) is exploring the possibility of a number of business opportunities and transactions. We recognize and appreciate the contributions you have made to the Company during your employment and want you to remain committed to and focused on the tasks that you are assigned during this time.
LICENSE AGREEMENTLicense Agreement • March 20th, 2017 • Cerulean Pharma Inc. • Pharmaceutical preparations • Delaware
This license agreement (the “Agreement”) is made and is effective as of March 19th, 2017 (the “Effective Date”) between BlueLink Pharmaceuticals, Inc. (“Licensee”) and Cerulean Pharma Inc. (“Licensor”). Licensee and Licensor are each referred to as a “Party” and collectively referred to as the “Parties.”
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • March 20th, 2017 • Cerulean Pharma Inc. • Pharmaceutical preparations • Delaware
Asset Purchase Agreement (“Agreement”), dated March 19, 2017 (the “Effective Date”) between BlueLink Pharmaceuticals, Inc., a Delaware corporation (“COMPANY”) and Cerulean Pharma Inc., a Delaware corporation (“Cerulean”). COMPANY and Cerulean are each separately referred to as a “Party” and are collectively referred to as the “Parties”.
